Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Alright, Alex, let's start with the headline numbers because they're pretty solid.

ALEX: Yeah, Vertex posted $3.3 billion in total revenue for Q2, up 12% year-over-year. That's driven largely by the cystic fibrosis franchise, which grew 11%, but also some real acceleration from the newer products.

JORDAN: Right, and this is the part I find genuinely interesting — CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, brought in $76 million this quarter. That's roughly 75% sequential growth and over 150% year-over-year. They had more infusions in the first half of 2026 than in all of 2025 combined.

ALEX: That's a huge inflection point. And it's not slowing down either — they had over 100 patient initiations for a third straight quarter, plus a pediatric approval for ages two to eleven that came through in just 53 days post-filing.

JORDAN: Then there's JOURNAVX, their non-opioid pain drug, at $50 million in revenue — about 70% sequential growth. The prescription numbers are climbing fast too, roughly 535,000 scripts this quarter. But here's the nuance: gross-to-net is still messy because of a patient support program covering people whose insurance has restrictions like quantity limits.

ALEX: Management said that normalizes more toward branded-drug norms in the first half of 2027, so investors watching margins on JOURNAVX should expect some lumpiness for a few more quarters.

JORDAN: On profitability — non-GAAP EPS came in at $4.73, up 5% year-over-year. Gross margin was 85.6%, a slight step down from Q1, which they attributed to product mix as CASGEVY, which costs more to manufacture, becomes a bigger slice of revenue.

ALEX: And they raised full-year revenue guidance to $13.1 to $13.2 billion, reiterating that $500 million-plus target for non-CF revenue this year.

JORDAN: Now let's talk about the big strategic move — the Crinetics Pharmaceuticals acquisition. This is roughly an $8.8 billion deal, expected to close in Q3.

ALEX: This is Vertex adding a fifth commercial pillar — rare endocrine diseases like acromegaly, CAH, and Cushing's syndrome. The two lead assets from Crinetics, paltusotine and atumelnant, are pegged at a combined peak sales opportunity of about $5 billion.

JORDAN: It's being funded through cash on hand plus a $4.5 billion term loan, and management said it should become accretive to operating income in 2029 — so this is a multi-year bet, not an immediate earnings boost.

ALEX: Let's talk pipeline, because there's a lot moving. The renal franchise is arguably the most important near-term catalyst — povetacicept, or "Povi," for IgA nephropathy has an FDA decision date of November 30th after a really strong phase III interim analysis.

JORDAN: And on the call, Reshma Kewalramani, the CEO, made a pretty confident case for Povi's differentiation — she cited a 52% reduction in proteinuria, which she called numerically the best in class, plus once-monthly dosing via a small-volume auto-injector patients can use at home.

ALEX: There was also a great analyst question about how Vertex sees eGFR data compare against a competitor's recently published numbers. Reshma's answer was essentially: strong proteinuria reduction should translate to GFR stabilization, and Vertex believes Povi's numbers on proteinuria, hematuria, and other biomarkers

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
BETA FINCH — Uber Technologies (UBER) Q2 2026 Earnings Breakdown

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

JORDAN: And I'm Jordan. Today we're digging into Uber's second quarter 2026 results — and Alex, this was a loaded call. Delivery Hero, autonomous vehicles, a Waymo update — there's a lot here.

ALEX: There really is. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, let's get into the numbers.

ALEX: So gross bookings came in at more than $58 billion, up 22% year-over-year — that's above the high end of guidance, and it's the fourth straight quarter above 20% growth. Non-GAAP EPS was up 35%, and trailing 12-month free cash flow crossed $10 billion for the first time ever.

JORDAN: That free cash flow number is the headline for me. Ten billion trailing twelve months — that's real operating leverage, not just top-line growth. And it's giving them room to do something pretty aggressive: the agreement to acquire Delivery Hero.

ALEX: Right, and that deal basically doubles the number of markets where Uber can run both mobility and delivery side by side — pushing them toward nearly 100 markets. CFO Balaji Krishnamurthy laid out the integration timeline: assuming a close in the second half of 2027, they'd spend 2028 planning, then execute the core platform migration in 2029.

JORDAN: That's a long runway. And notably, they actually pivoted about $4 billion of capital toward that deal in Q2 — buying Delivery Hero stock on the open market to be ready to move fast. That's part of why buybacks slowed to $3.5 billion so far this year instead of hitting their usual 50%-of-free-cash-flow pace. Balaji said they're "steadily" rebuilding repurchases — and when pushed on timing, he said months, not quarters.

ALEX: Let's talk autonomous vehicles, because Dara Khosrowshahi spent a lot of time here. Uber's live in seven cities with AV partners right now, on track for 15 by year-end — Zoox in Vegas, Wayve in London and Tokyo, a Nuro-Lucid launch in the Bay Area, Baidu, Pony, more.

JORDAN: What stood out to me is how he framed the whole AV landscape — comparing it to the foundation model race. Instead of one company winning everything, you get multiple players — Waymo, Zoox, Wayve, Nuro, Rivian, NVIDIA — and Uber's positioning itself as the commercialization layer underneath all of them, not betting on a single winner.

ALEX: Which matters given the Waymo headlines lately. Dara addressed it directly — said Waymo remains an important partner, they'll keep operating in Austin and Atlanta into next year, but Uber's deliberately diversifying so they're not dependent on one AV provider.

JORDAN: And the scale context he gave was useful — AVs are doing hundreds of thousands of trips per week against Uber's total of 300 million weekly trips. That's under half a percent of volume. So this is very much still an early-innings story, even with all the partnership headlines.

ALEX: There was also a really interesting tidbit on the economics — Dara said Uber's built-in demand drives utilization of mid-to-high-20s, even low-30s trips per vehicle per day for AV partners. That's a meaningful data point on how Uber's platform accelerates the monetization case for these robotaxi partners.

JORDAN: On the U.S. mobility side, Balaji broke down what's driving the acceleration everyone's been watching for — insurance cost savings being reinvested into markets like California, product innovation on both ends of the spectrum — Uber Reserve and Black on the premium side, Wait & Save on the value side — and then sparse markets, where less than 10% of eligible U.S. consumers have used Uber in the past year, versus over

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL)
──────────
**BETA FINCH — TJX Companies (TJX) Q2 Fiscal 2027 Earnings Breakdown**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

JORDAN: And I'm Jordan. Today we're digging into TJX Companies — the parent of TJ Maxx, Marshalls, HomeGoods, and Sierra — and their second quarter fiscal 2027 results.

ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good to have that out of the way. So, Alex, headline number first — how'd they do?

ALEX: Pretty strong quarter overall. Consolidated comp sales up 4%, which beat their own plan. Adjusted diluted EPS came in at $1.22, up 11% year-over-year, and also well above what they'd guided to. Off the back of that, they actually raised full-year guidance — now looking at $5.15 to $5.20 in adjusted EPS for the year, up 9-10% from last year.

JORDAN: That's a solid beat-and-raise. But there was one wrinkle in there — Marmaxx, which is their biggest division by far, TJ Maxx and Marshalls combined, only grew comps 1%. Everybody else was humming.

ALEX: Right, and that's really the story of this call. HomeGoods put up a 7% comp, TJX Canada was up 6%, and TJX International — that's Europe and Australia — was up 7% as well. Those three carried the quarter while Marmaxx lagged.

JORDAN: CEO Ernie Herrman was pretty candid about what happened there. He called it "self-inflicted" — basically said they didn't have the right merchandise mix in the right stores at the right time. Not a demand problem, not a competitive pricing problem.

ALEX: Yeah, and he made a point of saying they actually checked — their comps near direct off-price competitors were basically identical to comps in stores without nearby competition. So this wasn't about getting out-priced by anyone. It was execution — certain categories where they just didn't have enough of the right inventory, so shoppers walked in and couldn't find what might've been an impulse buy.

JORDAN: What I found interesting is he framed the fix as already underway — said sales were improving into August, and he expects to be back to that normal 2-3% comp range for Marmaxx by the fourth quarter, in time for holiday.

ALEX: They also said they've built in some new systematic planning processes to catch this kind of mix issue earlier. And notably, everyone from buyers up to Herrman himself was looped into fixing it — so it sounds like this got serious internal attention.

JORDAN: Meanwhile, HomeGoods was the real standout. Let's talk about that — 7% comp, and adjusted segment profit margin jumped 240 basis points to 12.4%. That's a big move.

ALEX: Herrman was genuinely excited about that one. He talked about HomeGoods becoming this dual-purpose destination — not just the treasure-hunt impulse shopping people associate with it, but now also a place people go for everyday consumable staples, like replenishing kitchen or home goods regularly. That combination is driving really consistent traffic.

JORDAN: And on the margin side, CFO John Kirby noted it's a mix of the sales leverage from that strong comp, some operational efficiencies, and lower tariff costs boosting merchandise margin.

ALEX: Speaking of tariffs — that's a thread running through this whole call. TJX actually received tariff refunds during the quarter, and all the numbers we're discussing are on an adjusted basis that strips those out, along with some related compensation accruals tied to them.

JORDAN: Worth flagging for listeners — gross margin was up 70 basis points to 31.4% in the quarter, largely tariff-driven favorability. But looking into the back half, management guided gross margin roughly flat to slightly down

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)
──────────
WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWN.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Palantir's Q2 2026 print — and folks, this one's a doozy. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And we need that disclaimer today more than usual, because Alex Karp did not hold back on this call. But let's start with the numbers, because they're genuinely wild. Revenue grew 93% year-over-year — that's Palantir's highest growth rate ever, at this scale.

ALEX: Right, and it's not a small-company effect either. We're talking $1.935 billion in quarterly revenue. The U.S. business specifically grew 115% year-over-year and is now over 81% of total revenue. U.S. commercial — meaning private companies, not government — accelerated to 149% year-over-year growth. That's up from an already huge number last quarter.

JORDAN: The bookings numbers back that up too. They closed $2.132 billion in U.S. commercial TCV — total contract value — in a single quarter. That's nearly $800 million above their previous best quarter ever. And 220 deals worth a million dollars or more, 73 of those over $10 million. Net dollar retention hit 157%, up 700 basis points sequentially — meaning existing customers aren't just staying, they're massively expanding their spend.

ALEX: On profitability, this wasn't a "growth at all costs" story either. Adjusted free cash flow was $1.22 billion, a 63% margin. GAAP net income crossed a billion dollars for the first time. Rule of 40 score — that combines growth plus margin — hit 155. For context, 40 is considered good for software companies. They're at nearly four times that.

JORDAN: And they raised guidance meaningfully. Full-year revenue guidance moved up to around $8.15 billion, which they called their largest-ever guidance raise. U.S. commercial guidance now sits above $3.4 billion for the year, implying at least 134% growth.

ALEX: So let's talk strategy, because CTO Shyam Sankar and CEO Alex Karp spent a lot of time on this idea of "AI sovereignty." The pitch is basically: if you're an enterprise just buying tokens from a frontier AI lab, you're paying to leak your own proprietary data and expertise into that lab's training pipeline — helping them build tools that could eventually compete with you. Palantir's argument is that their platform, AIP, lets companies keep control of their data, their models, and the "weights" — meaning the actual trained intelligence — inside their own security boundary.

JORDAN: There was a great anecdote about this — Shyam described a bake-off at a major tech company between a frontier AI lab's team and Palantir's forward-deployed engineers. Same customer, same timeline, same underlying models. The lab reportedly failed to deliver on a ticketing automation problem, while Palantir's team built something that converted into a $10 million contract. Whether or not you love the framing, it's a concrete data point on why enterprises are choosing them.

ALEX: They also introduced this term "benchmaking" versus "benchmaxing" — basically arguing that generic AI benchmarks don't matter much; what matters is building a benchmark specific to your business and optimizing toward that. They gave an example where an open-weight model, Nemotron Ultra, with no extra tuning, beat frontier models on five actual production tasks within 24 hours of testing.

JORDAN: On the government side — which is still nearly half of total revenue — U.S. government revenue grew 90% year-over-year. Their Maven platform now has over 25,000 builders

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Pfizer's second quarter 2026 results, and there's a lot to unpack — from a CFO transition to some really important pipeline news. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And there's plenty to research here, Alex. Let's start with the headline news that isn't even about the numbers — Pfizer's CFO Dave Denton is departing, and Cecile Guegan is stepping in as interim CFO. She's not new to the building though — she's been deeply involved in the Seagen, Metsera, and Biohaven deals and Pfizer's capital allocation strategy.

ALEX: Right, so this feels like a continuity move rather than a shake-up. Now let's get to the numbers. Q2 revenue came in at $15 billion, up just 1% operationally year-over-year — but here's the key detail: strip out COVID products, and the underlying business actually grew 5% operationally.

JORDAN: That's the story of this whole quarter — COVID is a drag, everything else is humming. Adjusted diluted EPS was $0.77, beating expectations. And get this — Pfizer has now beaten EPS expectations for ten straight quarters, and revenue expectations in nine of the last ten. That's a pretty remarkable execution streak.

ALEX: They also raised full-year revenue guidance to a range of $60.5 to $62.5 billion, up $500 million at the midpoint, even while cutting their COVID revenue forecast from $5 billion to $4 billion.

JORDAN: Which tells you how strong the non-COVID business is performing to more than offset that. EPS guidance was reaffirmed at $2.80 to $3, though that now absorbs a $0.10 hit from the Innovent Biologics deal that closed in Q3.

ALEX: Let's talk about those big acquisitions, because this is really the crux of Pfizer's growth story. The Seagen, Metsera, and Biohaven deals — revenue from acquired products grew 25% operationally. PADCEV, the bladder cancer drug from Seagen, just got FDA approval expanded to muscle-invasive bladder cancer regardless of cisplatin eligibility, and it grew over 20% this quarter.

JORDAN: And on the Metsera side, that's the obesity bet — nirubenatide, their monthly GLP-1 candidate. They're targeting a $150 billion obesity market and aiming for first approval in 2028. They shared data suggesting it could be competitive with — maybe even better than — some existing weekly therapies like Wegovy, though as always, cross-trial comparisons come with caveats.

ALEX: Biohaven's NURTEC is also doing well, still leading the oral CGRP migraine class, with new trials underway for chronic and menstrual migraine.

JORDAN: Now, it wasn't all good news. There was a real setback in oncology — the phase III trial for sigvotatug vedotin, or SV, missed its primary overall survival endpoint in second-line-plus non-small cell lung cancer. That contributed to a $4.3 billion non-cash impairment charge, which is why Pfizer actually posted a GAAP loss per share of $0.04 this quarter.

ALEX: But management pushed back on writing off SV entirely — they highlighted a subgroup of patients on just one prior therapy that showed a 2.5-month survival benefit, and they're leaning into earlier-line lung cancer combos with pembrolizumab, where phase I data showed an 82% response rate.

JORDAN: There's also encouraging news on mevrometostat, their prostate cancer drug being developed alongside XTANDI. Phase I data showed it roughly doubled progression-free survival, and the market really zeroed in on this during Q&A — analysts are watching the MEV-Pro1 readout expected in Q4.

ALEX: Speaking of Q&A, one exchange I found telling was about the dividend. An analyst

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: MAG7 (https://betafinch.com/groups/MAG7), CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)
──────────
**Beta Finch: NVIDIA Q2 FY2027 Earnings Breakdown**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into NVIDIA's fiscal Q2 2027 print — and there's a lot to unpack.

ALEX: Before we get into it — quick note. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Alright, with that out of the way — Alex, NVIDIA just put up $96 billion in quarterly revenue. That's more than double year-over-year.

ALEX: And it's the fourth straight quarter of accelerating growth, which is honestly wild for a company already this large. Data center revenue alone hit $89 billion, up 18% sequentially. Split that into two buckets: hyperscale revenue was $49 billion, up 13%, and then this other segment they call ACIE — that's NeoClouds, enterprise, sovereign AI — came in at $40 billion, up 25% sequentially and 138% year-over-year.

JORDAN: That ACIE number jumps out to me. It's growing faster than the hyperscale business, and CFO Colette Kress made a point of saying it now represents roughly half of NVIDIA's data center business. That's not a side hustle anymore — sovereign AI alone tripled year-over-year.

ALEX: Right, and they're guiding Q3 revenue to $108 billion, plus or minus 2%. For the full fiscal year 2028, they're now projecting about 70% revenue growth — but here's the catch, Jordan.

JORDAN: The catch is that's a supply-constrained number, not a demand number. Jensen Huang was pretty blunt on the call — actual demand is closer to 100% growth. They simply can't build enough. Every cloud they serve is fully utilized.

ALEX: Which is a good problem to have, but it does mean gross margins are getting squeezed. Memory pricing — DRAM specifically — has spiked way beyond what they expected. Gross margin is guided down to 74% in Q3, and they said it'll bottom out around 71-72% in Q4 before recovering to 72-73% next fiscal year once price increases kick in.

JORDAN: That's the number I think investors are going to fixate on. Component costs eating into margins is a real headwind, even with revenue this strong.

ALEX: Let's talk strategy, because there's a lot of new stuff here. First, the AWS expansion — Amazon's deploying an additional 2 million GPUs through fiscal 2029, plus their new Vera CPUs, some paired with the upcoming Rubin GPU.

JORDAN: And Vera Rubin itself is the big story architecturally. They started production shipments this month, and Jensen's calling it the fastest product ramp in company history — already has purchase orders from every major hyperscaler, cloud, and OEM. The pitch is 30x higher throughput per megawatt and 35x lower token cost versus the previous Blackwell Ultra generation.

ALEX: There's also this revenue-per-gigawatt trend they keep highlighting. Hopper was about $18 billion of NVIDIA revenue opportunity per gigawatt of data center capacity. Blackwell pushed that to $25 billion. Vera Rubin is $40 billion.

JORDAN: That's the flywheel — each generation captures a bigger slice of the data center build-out, not just GPUs but CPUs, networking, even their new Groq LPU line for high-speed inference. It's less "sell a chip" and more "sell the whole factory."

ALEX: Speaking of financing — this is where it gets a little more complicated. NVIDIA disclosed nearly $50 billion invested directly into frontier AI labs, plus new financing partnerships with six major capital providers — Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs, KKR — aiming to raise over $500 billion in third-party capital for AI infrastructure.

JORDAN: And they address

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown for the news that's moving your portfolio.

ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan as always, and today we're digging into Merck's second quarter 2026 numbers. Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good disclaimer to lead with, because there's a lot to unpack here — this was a noisy quarter on paper but honestly a pretty exciting one underneath the hood.

ALEX: Right, let's start with the headline numbers. Merck posted revenue of $16.6 billion, up 5%, or 4% if you strip out currency effects. Oncology and animal health carried a lot of that weight, plus growing contributions from newer launches.

JORDAN: But here's where it gets interesting — on the bottom line, Merck actually reported a loss of $0.13 per share. That sounds alarming until you realize it's almost entirely a one-time accounting quirk.

ALEX: Exactly. They completed the acquisition of Terns Pharmaceuticals this quarter, picking up a promising CML — chronic myeloid leukemia — drug candidate. That came with a $5.7 billion charge, and because it wasn't tax-deductible, their tax rate for the quarter ballooned to over 160%.

JORDAN: Which tanked EPS by $2.31 a share. Take that out, and the underlying business is actually performing quite well. It's a classic case of "read past the GAAP headline number."

ALEX: They also raised and narrowed full-year guidance — now expecting revenue between $66.3 and $67.3 billion, 2-4% growth, and full-year EPS of $2.66 to $2.76.

JORDAN: Let's talk product performance, because this is really a story of "old reliable" versus "new and exciting." KEYTRUDA, the flagship cancer immunotherapy, grew 4% to $8.4 billion — still the workhorse, but management flagged that U.S. growth is moderating as it approaches peak penetration in a lot of indications.

ALEX: Meanwhile the newer stuff is popping. WINREVAIR, their pulmonary hypertension drug, was up 75% to $588 million. WELIREG jumped 67%. CAPVAXIVE, their pneumococcal vaccine, up 40%.

JORDAN: Those growth rates matter a lot for the bigger narrative here, which is what happens when KEYTRUDA eventually loses patent exclusivity around the end of the decade. CEO Rob Davis addressed this directly in the Q&A — he called it "more of a hill than a cliff," with a shallow dip and a fast return to growth, backed by more than $70 billion in commercial opportunity from over 20 new products.

ALEX: And a big one this quarter was LIPFENDRA — the first oral PCSK9 inhibitor approved by the FDA, for lowering LDL cholesterol. It got fast-tracked through a national priority voucher process.

JORDAN: This is a big deal because current injectable PCSK9 drugs only reach about 5% of the eligible market — mostly because doctors and patients don't love needles for a chronic condition. An oral pill could meaningfully expand that market. Davis was clear they're not trying to steal share from injectables, they're trying to grow the whole pie — 30 million Americans are on lipid therapy but not hitting their LDL targets.

ALEX: There's also real pipeline momentum beyond LIPFENDRA. Sac-TMT, their Trop-2 antibody-drug conjugate for cancer, put up positive Phase III results in endometrial cancer — ahead of schedule. Same with tulisokibart, their ulcerative colitis drug, which hit positive Phase III results faster than expected too.

JORDAN: Dr. Dean Li, their research chief, made a point of saying their confidence is actually higher now than it was back in January, because so many of these pipeline bets are reading out early and positive. That's not something yo

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into McDonald's second quarter 2026 results, and there's a lot to unpack — some real strategic news alongside a leadership change. Before we get into it, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Yeah, and this one's juicy, Alex — because it's not the usual "everything's great" call. McDonald's actually came out and said, in Chris Kempczinski's words, "we don't have a strategy problem, we simply didn't execute."

ALEX: Right, so let's start with the numbers. Systemwide sales grew 4% in constant currency, global comparable sales up 1.3%. Adjusted EPS came in at $3.38, up 5% on a constant currency basis. Solid, but not spectacular.

JORDAN: And the real story is the U.S. — comp sales grew just 0.8% in the quarter, which was below expectations. International actually carried the day here, with IOM up 1.5% and the international developmental licensed markets up 1.9%, led by Japan posting its tenth straight quarter of positive guest counts.

ALEX: So what actually went wrong in the U.S.? CFO Ian Borden broke it into pieces. They launched this new "everyday affordable price" menu — 10 items under $3 — in late April, but execution was spotty. Only about 60 to 65% of restaurants actually followed the recommended pricing.

JORDAN: And here's the kicker — to fund that value push, they pulled back on digital offers and killed the Buy One, Add One for a dollar promotion, which apparently really annoyed their most loyal, high-frequency customers. Kempczinski flat-out called it "a bad trade."

ALEX: Management said that alone accounted for about two-thirds of the traffic miss. The rest came down to their FIFA-themed marketing campaign in June underperforming expectations.

JORDAN: There was also this operational overload problem — Chris painted a great picture of it, basically saying "put yourself in a restaurant manager's shoes." You've got K-Pop Demon Hunters merchandise going up, then three weeks later you're flipping the value menu, then a brand-new beverage platform launches, then FIFA. Crew members are getting whiplash, service times went up, satisfaction scores went down.

ALEX: It's a good reminder that even a company with McDonald's scale and marketing muscle can trip over its own to-do list. Too much "new" at once, poorly sequenced.

JORDAN: Right, and it bled into July too — Borden mentioned U.S. comps were actually slightly negative to start Q3. So this isn't fully behind them yet.

ALEX: Now here's where it gets interesting — there's a leadership shakeup. Skye Anderson, previously COO of McDonald's USA, is stepping in as the new President of McDonald's U.S., effective immediately. Joe Erlinger, who ran the U.S. business for nearly seven years, is leaving the company.

JORDAN: Chris was pretty deliberate about framing this as a planned transition, not a panic move — he name-checked Anderson's 26-year track record, including a stint leading the U.S. West zone where she drove over 30% comp sales growth. But the timing, right after a rough quarter, is obviously going to raise eyebrows.

ALEX: On the brighter side — beverages. McDonald's launched a new beverage platform in the U.S., Canada, and Germany in May, and early results are beating expectations. Higher checks, strong food attachment, and more than half the traffic is coming after the lunch rush — which is exactly the low-volume window they want to fill.

JORDAN: They're also leaning into Red Bull Energizers rolling out in the U.S. soon, and Australia just launched the platform in mid-July. This seems like a l

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Mastercard's second quarter 2026 results, and there's a lot to unpack — big numbers, a leadership shakeup, and some fascinating moves into AI-driven commerce.

JORDAN: Yeah, this one's got a bit of everything. But before we get into it —

ALEX: Right, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, now let's get into it. Mastercard posted net revenue up 12% year-over-year, adjusted net income up 16%, and EPS of $5.04. That's a strong quarter, and honestly it came in above what management was expecting.

ALEX: It really did. And one number that jumped out to me — value-added services, that's all the fraud, security, and consulting stuff Mastercard layers on top of its payments network — grew 18%. That's outpacing the core payments business by a good margin.

JORDAN: Which tells you where the growth engine really is right now. Gross dollar volume worldwide was up 8%, cross-border volume up 12%, and switched transactions — that's transactions actually processed on Mastercard's network — grew 9%. All pretty healthy.

ALEX: Let's talk about the elephant in the room first, though: the leadership transition. This was CFO Sachin Mehra's last earnings call in that role — he's moving to a new position as Chief Business Officer. Ling Hai, who's been running the Asia Pacific, Europe, Middle East and Africa region, steps in as CFO starting August 3rd.

JORDAN: It was a pretty warm moment on the call, honestly. CEO Michael Miebach thanked Mehra for seven-plus years in the seat, and Mehra himself got a little sentimental, thanking analysts and investors for the relationship. Ling Hai even said he's looking forward to "leading the next earnings call."

ALEX: Smooth transition, no red flags — just feels like normal succession planning at a company that's performing well.

JORDAN: Agreed. Now, strategically, there were a few things I found really interesting. First, this switching technology partnership in the UAE. Mastercard is now building out the actual domestic payments switching infrastructure for the Central Bank of the UAE, working alongside their local scheme called Jaywan.

ALEX: Which is a bit of a shift, right? Normally we think of Mastercard as just the network sitting on top of transactions. Here they're actually building and operating switching infrastructure locally.

JORDAN: Exactly — Miebach called it "run anything anywhere," a strategy they've been building since 2022. They've done something similar in South Africa, and they're clearly eyeing this modular approach as a way to get access to transaction volume they wouldn't otherwise touch — even domestic transactions that don't run through Mastercard's global switch.

ALEX: There's also a Latin America push — expanding their Alipay+ partnership into Mexico with Clip, a fintech with a huge merchant network. Remember, Mexico is a market where over 70% of consumer payments are still cash-based, so there's a massive digitization opportunity there.

JORDAN: And speaking of frontier stuff — Mastercard rolled out something called Agent Pay for Machines. This is genuinely new territory: it's designed to let AI agents autonomously pay for things like API calls, cloud compute, or data access, at machine speed, with over 30 partners already signed on including Coinbase, Cloudflare, and Checkout.com.

ALEX: This is the "agentic commerce" trend everyone's talking about. Miebach made an interesting distinction on the call — consumer and B2B agent-driven purchases can basically run through existing card rails just fine, but this true machine-to-machine, micro-transaction world is a genuinely new category, and Mast

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL)
──────────
I'll write the podcast script now based on the transcript.

WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWN

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Lowe's second quarter fiscal 2026 results, reported August 19th. Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good disclaimer to lead with, because this quarter has a little bit of everything — solid execution undercut by some messy competitive dynamics. Should be a fun one to unpack.

ALEX: Let's start with the topline. Lowe's did $26 billion in sales for the quarter, up 8.3% year-over-year, but that growth is mostly acquisition-driven — comparable sales, meaning existing stores, only rose 0.2%. GAAP diluted EPS came in at $4.27, and adjusted EPS was $4.40, which included an $0.11 benefit from tariff refunds.

JORDAN: And that $0.11 detail matters more than it sounds like at first. CFO Brandon Sink was clear that even excluding the tariff refund, adjusted EPS beat expectations. So the underlying business performed better than the headline number suggests — that refund wasn't propping up an otherwise weak quarter.

ALEX: Right, and comp sales broke down interestingly by month — May was down 0.4%, June up 1.7%, July down 1.2%. Some of that swing is just calendar noise, the July 4th holiday shifted between June and July and moved about 75 basis points back and forth.

JORDAN: But the more important July story wasn't calendar — it was competitive. Management said competitors used their own tariff refund dollars to slash prices, particularly in seasonal categories like grills, patio furniture, and live goods. Lowe's chose not to chase those promotions.

ALEX: Yeah, CEO Marvin Ellison was pretty blunt about that in the Q&A — he said matching those prices "was not in our financial plan" and wasn't "financially prudent." Basically: we can see who got tariff refunds by looking at whose gross margin cratered.

JORDAN: Which is a pretty sharp comment aimed squarely at competitors. But it also tells you something about Lowe's discipline here — they'd rather protect margin than chase a short-term share number in a category they view as transitory. Whether that's the right call long-term is the real debate for investors.

ALEX: Let's talk about where the strength actually showed up, because it wasn't uniform. Lowe's has been leaning hard into what they call the "Total Home" strategy — basically diversifying beyond the DIY homeowner into professional contractors, online, and installed services.

JORDAN: And that strategy is clearly doing the heavy lifting. Online sales grew nearly 16% — that's back-to-back quarters above 15%. Pro customers kept growing too, especially small and medium-sized contractors. Home Services, the "do it for me" installation business, also grew. Meanwhile, discretionary DIY spending — think big remodeling projects — stayed under pressure.

ALEX: One thing that jumped out to me was Mylow, their AI shopping assistant. They said it's fielded over 25 million questions from customers and store associates combined, and customers who use it convert at three times the rate of those who don't.

JORDAN: That's a genuinely strong stat. It's early days for how much AI tools move the needle in retail, but a 3x conversion lift is not a rounding error — that's a real behavioral signal. Worth watching whether that holds up as adoption scales further.

ALEX: On the Pro side, they've been building out FBM and ADG — Foundation Building Materials and Artisan Design Group, two acquisitions aimed at bigger professional and construction customers

This episode includes AI-generated content.